Is Pharvaris Stock a Good Investment?
Pharvaris Investment Advice | PHVS |
- Examine Pharvaris' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pharvaris' leadership team and their track record. Good management can help Pharvaris navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Pharvaris' business and its evolving consumer preferences.
- Compare Pharvaris' performance and market position to its competitors. Analyze how Pharvaris is positioned in terms of product offerings, innovation, and market share.
- Check if Pharvaris pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pharvaris' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pharvaris BV stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pharvaris BV is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pharvaris Stock
Researching Pharvaris' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 88.0% of the company shares are owned by institutional investors. The book value of Pharvaris was at this time reported as 7.35. The company recorded a loss per share of 2.72. Pharvaris BV had not issued any dividends in recent years.
To determine if Pharvaris is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pharvaris' research are outlined below:
| Pharvaris BV had very high historical volatility over the last 90 days | |
| Net Loss for the year was (99.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pharvaris BV currently holds about 201.38 M in cash with (93.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.96. | |
| Pharvaris BV has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Pharvaris reports Q3 results |
Pharvaris uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pharvaris BV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pharvaris' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pharvaris' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pharvaris' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -0.6043 | -0.77 | -0.1657 | 27 | ||
2022-09-12 | 2022-06-30 | -0.57 | -0.38 | 0.19 | 33 | ||
2024-03-06 | 2023-12-31 | -0.58 | -0.82 | -0.24 | 41 | ||
2022-12-08 | 2022-09-30 | -0.63 | -0.25 | 0.38 | 60 | ||
2023-04-05 | 2023-03-31 | -0.65 | -1.17 | -0.52 | 80 | ||
2022-12-31 | 2022-12-31 | -0.7 | -1.25 | -0.55 | 78 | ||
2021-07-30 | 2021-06-30 | -0.39 | -0.94 | -0.55 | 141 | ||
2022-03-29 | 2021-12-31 | -0.71 | -0.09 | 0.62 | 87 |
Pharvaris Target Price Consensus
Pharvaris target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Pharvaris' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Pharvaris analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Pharvaris stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Pharvaris BV, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPharvaris Target Price Projection
Pharvaris' current and average target prices are 22.36 and 24.15, respectively. The current price of Pharvaris is the price at which Pharvaris BV is currently trading. On the other hand, Pharvaris' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Pharvaris Market Quote on 28th of November 2024
Target Price
Analyst Consensus On Pharvaris Target Price
Pharvaris Analyst Ratings
Pharvaris' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Pharvaris stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Pharvaris' financials, market performance, and future outlook by experienced professionals. Pharvaris' historical ratings below, therefore, can serve as a valuable tool for investors.Pharvaris' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.31 B.Market Cap |
|
Pharvaris' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.26) | (0.28) |
Determining Pharvaris' profitability involves analyzing its financial statements and using various financial metrics to determine if Pharvaris is a good buy. For example, gross profit margin measures Pharvaris' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pharvaris' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pharvaris' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pharvaris BV. Check Pharvaris' Beneish M Score to see the likelihood of Pharvaris' management manipulating its earnings.
Evaluate Pharvaris' management efficiency
Pharvaris BV has return on total asset (ROA) of (0.2679) % which means that it has lost $0.2679 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4505) %, meaning that it created substantial loss on money invested by shareholders. Pharvaris' management efficiency ratios could be used to measure how well Pharvaris manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.26 in 2024. At this time, Pharvaris' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 885.3 K in 2024, whereas Return On Tangible Assets are likely to drop (0.27) in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.00 | 10.50 | |
| Tangible Book Value Per Share | 10.00 | 10.50 | |
| Enterprise Value Over EBITDA | (6.02) | (6.32) | |
| Price Book Value Ratio | 2.54 | 2.41 | |
| Enterprise Value Multiple | (6.02) | (6.32) | |
| Price Fair Value | 2.54 | 2.41 | |
| Enterprise Value | 583.2 M | 522.7 M |
The leadership approach at Pharvaris' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta (3.15) |
Basic technical analysis of Pharvaris Stock
As of the 28th of November, Pharvaris holds the Semi Deviation of 2.99, coefficient of variation of 907.19, and Risk Adjusted Performance of 0.0923. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharvaris, as well as the relationship between them. Please check Pharvaris BV market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Pharvaris BV is priced some-what accurately, providing market reflects its current price of 22.36 per share. Given that Pharvaris has jensen alpha of 0.2454, we recommend you to check out Pharvaris BV's recent market performance to make sure the company can sustain itself at a future point.Pharvaris' Outstanding Corporate Bonds
Pharvaris issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pharvaris BV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pharvaris bonds can be classified according to their maturity, which is the date when Pharvaris BV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Pharvaris' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pharvaris' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0923 | |||
| Market Risk Adjusted Performance | 0.295 | |||
| Mean Deviation | 2.94 | |||
| Semi Deviation | 2.99 | |||
| Downside Deviation | 3.28 | |||
| Coefficient Of Variation | 907.19 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.56 | |||
| Information Ratio | 0.0772 | |||
| Jensen Alpha | 0.2454 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | 0.0928 | |||
| Treynor Ratio | 0.285 | |||
| Maximum Drawdown | 21.41 | |||
| Value At Risk | (6.02) | |||
| Potential Upside | 7.76 | |||
| Downside Variance | 10.76 | |||
| Semi Variance | 8.94 | |||
| Expected Short fall | (3.63) | |||
| Skewness | 0.2924 | |||
| Kurtosis | 0.9821 |
| Risk Adjusted Performance | 0.0923 | |||
| Market Risk Adjusted Performance | 0.295 | |||
| Mean Deviation | 2.94 | |||
| Semi Deviation | 2.99 | |||
| Downside Deviation | 3.28 | |||
| Coefficient Of Variation | 907.19 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.56 | |||
| Information Ratio | 0.0772 | |||
| Jensen Alpha | 0.2454 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | 0.0928 | |||
| Treynor Ratio | 0.285 | |||
| Maximum Drawdown | 21.41 | |||
| Value At Risk | (6.02) | |||
| Potential Upside | 7.76 | |||
| Downside Variance | 10.76 | |||
| Semi Variance | 8.94 | |||
| Expected Short fall | (3.63) | |||
| Skewness | 0.2924 | |||
| Kurtosis | 0.9821 |
Consider Pharvaris' intraday indicators
Pharvaris intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pharvaris stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 22459.51 | |||
| Daily Balance Of Power | (0.57) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 22.92 | |||
| Day Typical Price | 22.73 | |||
| Price Action Indicator | (1.46) | |||
| Period Momentum Indicator | (1.81) | |||
| Relative Strength Index | 42.53 |
Pharvaris Corporate Filings
6K | 13th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 12th of April 2024 Other Reports | ViewVerify | |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pharvaris Stock media impact
Far too much social signal, news, headlines, and media speculation about Pharvaris that are available to investors today. That information is available publicly through Pharvaris media outlets and privately through word of mouth or via Pharvaris internal channels. However, regardless of the origin, that massive amount of Pharvaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pharvaris news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pharvaris relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pharvaris' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pharvaris alpha.
Pharvaris Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pharvaris can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pharvaris Corporate Management
| Peng MD | Chief Officer | Profile | |
| Morgan Conn | Chief Officer | Profile | |
| Jochen Knolle | Chief COO | Profile | |
| CPA MBA | CEO CoFounder | Profile | |
| Joan JD | Chief Officer | Profile | |
| Stefan Abele | Chief Officer | Profile | |
| Wim Souverijns | Chief Officer | Profile |
Additional Tools for Pharvaris Stock Analysis
When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.